Company: NBE Therapeutics
Job title: Chief Executive Officer & Founder
Ulf Grawunder is CEO of NBE-Therapeutics, a Swiss Biotech company that he founded in 2012 and which focuses on the development of “next-generation” antibody-drug conjugates for cancer therapy. Prior to that, Ulf had co-founded 4-Antibody in 2004, a Swiss therapeutic antibody engineering company, where he initially served as CEO and later as CSO, until the company was sold to US-based Agenus. Ulf is a Biochemist who did his PhD in the area of B cell Immunology at the Basel Institute for Immunology. After this he did several years of post-doctoral research at Washington University School of Medicine, St. Louis, and the University of Southern California, Los Angeles. After that he returned to Europe to continue research as principal investigator at the Basel Institute for Immunology, and the University of Basel, Switzerland, before he started his first Biotech company, 4-Antibody. Ulf also holds a Diploma of Technology Entrepreneurship from the University St. Gallen, School of Business, Switzerland (HSG, Hochschule St. Gallen), and he is part if the teaching faculty of the European Center for Pharmaceutical Medicine (ECPM) at the University of Basel, Switzerland. Ulf is advisor of a number of national and international organizations, including the scientific advisory board of the Bavarian Immunotherapies Network, BayImmuNet, Germany (www.bayimmunet.de), the jury of Venturekick, Switzerland (http://www.venturekick.ch), and the Board of the Swiss Biotech Association (SBA, www.swissbiotech.org).
Live Discussion & Question Time 9:40 am
day: Day Two
Road to Clinical Validation of NBE-002, a Novel PNU-anthracycline-based ROR1 Targeting iADC in Solid Tumours 9:20 am
Understand rationales for targeting ROR1 in solid tumour patients Analyse preliminary data from a phase I/IIa clinical study with NBE-002, a novel ROR1-targeting iADC Gain an overview of clinical study design and biomarker strategy for future efficacy studies, based on NBE-002’s mode of actionRead more
day: Day Two